Nintedanib plus pemetrexed/cisplatin followed by maintenance nintedanib for unresectable malignant pleural mesothelioma (MPM): An international, multicenter, randomized, double-blind, placebo-controlled phase II study.
Giorgio V. Scagliotti
Honoraria - AstraZeneca; Lilly; Pfizer; Roche
Natasha B. Leighl
No relevant relationships to disclose
Anna K. Nowak
Consultant or Advisory Role - Boehringer Ingelheim
Nick Pavlakis
Consultant or Advisory Role - Boehringer Ingelheim
Honoraria - Boehringer Ingelheim
Sanjay Popat
Research Funding - Boehringer Ingelheim
Jens Benn Sorensen
No relevant relationships to disclose
Jose Barrueco
Employment or Leadership Position - Boehringer Ingelheim
Rolf Kaiser
Employment or Leadership Position - Boehringer Ingelheim
Arsene-Bienvenu Loembe
Employment or Leadership Position - Boehringer Ingelheim
Martha Mueller
Employment or Leadership Position - Boehringer Ingelheim
Ute von Wangenheim
No relevant relationships to disclose
Martin Reck
Consultant or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Novartis; Pfizer; Roche
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Novartis; Pfizer; Roche